These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 31028836)

  • 1. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates.
    Mahalingaiah PK; Ciurlionis R; Durbin KR; Yeager RL; Philip BK; Bawa B; Mantena SR; Enright BP; Liguori MJ; Van Vleet TR
    Pharmacol Ther; 2019 Aug; 200():110-125. PubMed ID: 31028836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.
    Masters JC; Nickens DJ; Xuan D; Shazer RL; Amantea M
    Invest New Drugs; 2018 Feb; 36(1):121-135. PubMed ID: 29027591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.
    Nguyen TD; Bordeau BM; Balthasar JP
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates for cancer.
    Chau CH; Steeg PS; Figg WD
    Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
    Donaghy H
    MAbs; 2016; 8(4):659-71. PubMed ID: 27045800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches to improve the translation of safety, pharmacokinetics and therapeutic index of ADCs.
    Huang Q; Ravindra Pilvankar M; Dixit R; Yu H
    Xenobiotica; 2024 Aug; 54(8):533-542. PubMed ID: 38733255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation.
    Simmons JK; Burke PJ; Cochran JH; Pittman PG; Lyon RP
    Toxicol Appl Pharmacol; 2020 Apr; 392():114932. PubMed ID: 32109510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development.
    Hammood M; Craig AW; Leyton JV
    Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists.
    Mecklenburg L
    Toxicol Pathol; 2018 Oct; 46(7):746-752. PubMed ID: 30295169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
    Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
    Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo safety testing of Antibody Drug Conjugates.
    Pretto F; FitzGerald RE
    Regul Toxicol Pharmacol; 2021 Jun; 122():104890. PubMed ID: 33587934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates: A Comprehensive Review.
    Khongorzul P; Ling CJ; Khan FU; Ihsan AU; Zhang J
    Mol Cancer Res; 2020 Jan; 18(1):3-19. PubMed ID: 31659006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
    Malik P; Phipps C; Edginton A; Blay J
    Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates.
    Aoyama M; Tada M; Yokoo H; Demizu Y; Ishii-Watabe A
    Pharm Res; 2022 Jan; 39(1):89-103. PubMed ID: 34961908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Vedotin Antibody-Drug Conjugate Payload Drives Platform-Based Nonclinical Safety and Pharmacokinetic Profiles.
    Neff-LaFord HD; Carratt SA; Carosino C; Everds N; Cardinal KA; Duniho S; Schutten MM; Frantz C; Zuch de Zafra C; Harstad EB
    Mol Cancer Ther; 2024 Oct; 23(10):1483-1493. PubMed ID: 38692647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE; Cotreau M; Han TH; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.